gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · JNJHealthcarePharmaceuticals

Johnson & Johnson (JNJ)

$276.32+3.81%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$266.17▲ 42.90% in range
Earnings Oct 13, 2026Earnings Jul 15, 2026Earnings Apr 14, 2026
Nov 3, 2025Low $186.00 · High $278.43Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Johnson & Johnson closed at $276.32 on Nov 4, up 3.81%, 0.8% below its 52-week closing high. Volume of 9.8M shares was 1.30× its 20-day average (above normal).

Split-adjusted performance: +8.5% over one month, +23.0% over six months, +48.4% over one year.

In the quarter ended Sep 27, 2026, revenue was $25.40B, up 5.9% from a year earlier, with a net margin of 0.8%.

Short interest was 16.8M shares at the Oct 15 settlement, down 24.0% from the prior report (0.7% of float, 2.0 days to cover).

After its Oct 13 report (EPS beat estimates by 2.8%), the stock moved -3.7% from the close before to the close after.

Market cap$665.19B2.41B shares
Revenue · quarter$25.40B+5.9% YoY
Diluted EPS$0.09−95.8% YoY
P/E · TTM41.3×P/S 6.7×
Net margin0.8%Gross 68.1%
Dividend yield1.94%$1.34 last paid
52-week range186.00 – 278.43−0.8% from high
Volume9.8M1.30× 20-day avg
Volatility · 60d24.7%Annualised
Short % of float0.7%2.0 days to cover
Net cash-$27.42BCash $17.23B
Next earnings—Not scheduled
Split-adjusted performance
1W +1.9%1M +8.5%3M +7.5%6M +23.0%YTD +33.5%1Y +48.4%3Y +87.9%5Y +68.8%

Earnings reactions

History →
Oct 13−3.7%
Jul 15−1.5%
Apr 14+0.3%

Close before the report to close after it.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum83
Revenue growth50
Net margin70
Value (low P/E)28
Size100

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short16.8M−24.0% vs prior
Days to cover2.0Settled Oct 15
% of float0.7%
Short vol. 10d30.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
JNJJohnson & Johnson$276.32+3.81%+23.0%+5.9%0.8%41.3$665.19B
ABBVABBVIE$294.83+3.09%+43.8%+10.3%24.2%50.4$521.00BCompare
MRKMerck & Co.$150.36+3.93%+32.4%+5.1%−8.0%116.9$370.96BCompare
LLYEli Lilly &$1,417.99+0.61%+43.7%+38.6%26.4%45.8$1.26TCompare
ABTAbbott Laboratories$115.51+5.58%+33.8%+13.0%7.4%36.8$199.88BCompare
PFEPfizer$30.79+2.63%+16.1%+2.6%−1.6%40.5$175.49BCompare
VRTXVertex Pharmaceuticals$549.04+3.44%+28.4%+11.8%19.0%35.0$139.16BCompare
BMYBristol-Myers Squibb$64.19+4.02%+13.4%+5.7%25.6%14.1$131.21BCompare
REGNRegeneron Pharmaceuticals$930.67−4.39%+29.1%+36.3%38.1%20.0$96.28BCompare

News about Johnson & Johnson

All news →
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?Zacks Investment Research · 1d ago▼ NegativeJohnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.The Motley Fool · 5d ago▲ PositiveJNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?Zacks Investment Research · 5d ago▼ NegativeThe Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVieZacks Investment Research · Oct 28, 2026▲ PositiveSubcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancerGlobeNewswire Inc. · Oct 25, 2026▲ Positive

Quick answers

What does Johnson & Johnson do?
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech.
What is JNJ's market cap?
$665.19B, based on the Nov 4 close of $276.32.
What is JNJ's P/E ratio?
41.3× trailing-twelve-month earnings of $16.09B.
Does Johnson & Johnson pay a dividend?
Yes. The latest regular dividend was $1.34 per share (ex-date Aug 25), an annualised yield of 1.94%.
How much of JNJ is sold short?
16.8M shares, 0.7% of float, as of Oct 15, 2026.
What sector is JNJ in?
Healthcare, in the Pharmaceuticals industry.

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

HQ: New Brunswick, NJ140,800 employeesListed Sep 25, 1944jnj.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology